AstraZeneca responds to Macron in terms of vaccine efficacy

A member of the "Oxford" team that developed the "AstraZeneca" vaccine against Corona opposed the comments of French President Emmanuel Macron, which questioned the effectiveness of the vaccine in immunizing people aged 65 and over.

In response to a question by BBC Radio on Saturday about Macron's statement that the vaccine is "almost ineffective" in people over the age of 65, Professor John Bell said, "I am not sure of its source."

Bell acknowledged that the number of elderly participants in the original study was "small" at about 12%, and said, "But in vaccinology, the way you deal with this problem is to determine the level of immunity that the vaccine generates."

He added: "The elderly responded just as people in other age groups did, and there is really convincing evidence that this is a preventive vaccine for them."

He said, "I think this is part of Macron's demand management process for vaccines.

The response came after a crisis between Britain and the European Union against the backdrop of "AstraZeneca" announcement to postpone supplies of its vaccine to the bloc countries due to production problems and the need to meet the UK's needs.

On Friday, Macron told reporters, "What I can officially say is that the first results are not encouraging for those over the age of 60-65," adding that the available information on the "Oxford" and "AstraZeneca" vaccine "is very limited."

Source: Website